The overall goal of this HIVRAD Program is to develop a second generation HIV-1 vaccine based on recombinant adeno-associated virus (rAAV) vectors. The proposed research in this application builds on our experience with a first generation rAAV/HIV vaccine that is now being tested in Phase I human trials. Although the first generation vaccine is a promising candidate, we believe that substantial room for improvement remains. Based on our preliminary data, we have developed a series of hypothesis driven experiments to achieve this goal. We will enhance antigen-specific T cell responses to the vaccine by (i) significantly augmenting vaccine gene delivery and (ii) directly engaging and modifying host immune responses.
| Clark, K Reed; Walsh, Scott T R (2009) Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody. Protein Sci 18:2429-41 |
| Chen, Chun-Liang; Jensen, Ryan L; Schnepp, Bruce C et al. (2005) Molecular characterization of adeno-associated viruses infecting children. J Virol 79:14781-92 |
| Johnson, Philip R; Schnepp, Bruce C; Connell, Mary J et al. (2005) Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 79:955-65 |
